The Growth/Differentiation Factor 8 pipeline drugs market research report outlays comprehensive information on the Growth/Differentiation Factor 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Growth/Differentiation Factor 8 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Central Nervous System, Musculoskeletal Disorders, and Genetic Disorders which include the indications Obesity, Unspecified Metabolic Disorders, Spinal Muscular Atrophy (SMA), Neuromuscular Disorders, Osteoporosis, Muscle Atrophy, Duchenne Muscular Dystrophy, and Osteogenesis Imperfecta. It also reviews key players involved in Growth/Differentiation Factor 8 targeted therapeutics development with respective active and dormant or discontinued products.
The Growth/Differentiation Factor 8 pipeline targets constitutes close to 12 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, and Preclinical stages are 1, 3, 2, 2, and 4 respectively.
Growth/Differentiation Factor 8 overview
Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFβ) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
For a complete picture of Growth/Differentiation Factor 8’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
